87 related articles for article (PubMed ID: 720076)
21. Eighteen months contraception following subdermal insertion of silastic capsules containing norgestrienone.
Da Silva AR; Coutinho EM
Int J Fertil; 1978; 23(3):185-92. PubMed ID: 40892
[TBL] [Abstract][Full Text] [Related]
22. The effect of low-oestrogen combined pill, progestogen-only pill and medroxyprogesterone acetate on oral glucose tolerance test.
Kamau RK; Maina FW; Kigondu C; Mati JK
East Afr Med J; 1990 Aug; 67(8):550-5. PubMed ID: 2148146
[TBL] [Abstract][Full Text] [Related]
23. Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes.
Skouby SO; Kühl C; Mølsted-Pedersen L; Petersen K; Christensen MS
Am J Obstet Gynecol; 1985 Nov; 153(5):495-500. PubMed ID: 3933351
[TBL] [Abstract][Full Text] [Related]
24. Menstrual blood loss with contraceptive subdermal levonorgestrel implants.
Nilsson CG; Holma P
Fertil Steril; 1981 Mar; 35(3):304-6. PubMed ID: 6781939
[TBL] [Abstract][Full Text] [Related]
25. A study of glucose tolerance, serum transaminase and lipids in women using depot-medroxyprogesterone acetate and a combination-type oral contraceptive.
Tankeyoon M; Dusitsin N; Poshyachinda V; Larsson-Cohn U
Contraception; 1976 Aug; 14(2):199-214. PubMed ID: 949896
[No Abstract] [Full Text] [Related]
26. Comparative studies of the ethynyl estrogens used in oral contraceptives. VI. Effects with and without progestational agents on carbohydrate metabolism in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; De La Pena A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Aug; 30(2):146-53. PubMed ID: 98357
[TBL] [Abstract][Full Text] [Related]
27. Subdermal progestin implant contraception.
Darney PD
Curr Opin Obstet Gynecol; 1991 Aug; 3(4):470-6. PubMed ID: 1908716
[TBL] [Abstract][Full Text] [Related]
28. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
29. Effects of two oral contraceptive combinations, 0.125 mg desogestrel + 0.050 mg ethinylestradiol and 0.125 mg levonorgestrel + 0.050 mg ethinylestradiol on the adrenal function of healthy female volunteers.
Ruokonen A; Lund L; Nummi S; Alapiessa U; Viinikka L
Eur J Obstet Gynecol Reprod Biol; 1982 Jun; 13(4):259-65. PubMed ID: 6214438
[TBL] [Abstract][Full Text] [Related]
30. Contraceptive effectiveness of Silastic implants containing the progestin R-2323.
Coutinho EM; Da Silva AR; Carreira CM; Chaves MC; Adeodato Filho J
Contraception; 1975 Jun; 11(6):625-35. PubMed ID: 1137935
[TBL] [Abstract][Full Text] [Related]
31. Contraceptive steroid administration by subdermal implants: serum concentrations of R-2323, estrogen and progesterone in rhesus monkeys.
Bahgat MR; Atkinson LE
Contraception; 1977 Mar; 15(3):335-45. PubMed ID: 880812
[No Abstract] [Full Text] [Related]
32. [Changes in laboratory tests after treatment with a new contraceptive agent].
Cervantes LF; López Barcena J; Calderón Márquez JJ
Ginecol Obstet Mex; 1978 Apr; 43(258):285-97. PubMed ID: 80349
[No Abstract] [Full Text] [Related]
33. Ultrasonic visualization of NORPLANT subdermal contraceptive devices.
Thomsen RJ; Pasquale S; Nosher J
Int J Gynaecol Obstet; 1985 Jun; 23(3):223-7. PubMed ID: 2865186
[TBL] [Abstract][Full Text] [Related]
34. Blood glucose, insulin, cholesterol and triglyceride levels in women treated for six months with the weekly oral contraceptive R2323.
Spellacy WN; Mahan CS; Buhi WC; Dumbaugh VA; Birk SA
Contraception; 1978 Aug; 18(2):121-6. PubMed ID: 249676
[TBL] [Abstract][Full Text] [Related]
35. Long-term reversible contraception with levonorgestrel-releasing Silastic rods.
Roy S; Mishell DR; Robertson DN; Krauss RM; Lacarra M; Duda MJ
Am J Obstet Gynecol; 1984 Apr; 148(7):1006-13. PubMed ID: 6424474
[TBL] [Abstract][Full Text] [Related]
36. [Contraception with implanted gestagens].
Nielsen NC; Friis T; Schousen P; Manthorpe T; Osler M
Ugeskr Laeger; 1979 Nov; 141(45):3100-3. PubMed ID: 392858
[TBL] [Abstract][Full Text] [Related]
37. Steroidal compounds (injectable and implants) affecting spermatogenesis in men.
Frick J; Bartsch G; Marberger H
J Reprod Fertil Suppl; 1976 Sep; (24 suppl):35-47. PubMed ID: 63550
[TBL] [Abstract][Full Text] [Related]
38. Oral contraceptives and insulin receptor binding in normal women and those with previous gestational diabetes.
Skouby SO; Andersen O; Kühl C
Am J Obstet Gynecol; 1986 Oct; 155(4):802-7. PubMed ID: 3766633
[TBL] [Abstract][Full Text] [Related]
39. Contraception with d-norgestrel silastic rods. Plasma levels of d-norgestrel and influence on the ovarian function.
Weiner E; Johansson ED
Contraception; 1976 Nov; 14(5):551-62. PubMed ID: 987891
[No Abstract] [Full Text] [Related]
40. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
